CUI1 stringlengths 8 8 | RELA stringlengths 3 54 | CUI2 stringlengths 8 8 | Name1 stringlengths 1 2.86k ⌀ | Name2 stringlengths 1 2.86k ⌀ | Def1 stringlengths 1 8.95k ⌀ | Def2 stringlengths 1 8.95k ⌀ |
|---|---|---|---|---|---|---|
C0000618 | chemotherapy_regimen_has_component | C0279859 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280024 | mercaptopurine | mercaptopurine/methotrexate/prednisolone/vincristine protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280064 | mercaptopurine | Carmustine/Mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280075 | mercaptopurine | mercaptopurine/methotrexate/methylprednisolone/vincristine protocol | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280525 | mercaptopurine | Mercaptopurine/Methotrexate Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of mercaptopurine and methotrexate that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C0280528 | mercaptopurine | Mercaptopurine/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280642 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280643 | mercaptopurine | Asparaginase/Cytarabine/Mercaptopurine/Methotrexate/Prednisolone/Teniposide/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280649 | mercaptopurine | Asparaginase/Cytarabine/Mercaptopurine/Methotrexate/Prednisone/Teniposide | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280729 | mercaptopurine | Dactinomycin/Idarubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280730 | mercaptopurine | Carmustine/Cyclophosphamide/Dactinomycin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280775 | mercaptopurine | Cyclophosphamide/Etoposide/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280777 | mercaptopurine | Cyclophosphamide/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0280821 | mercaptopurine | Dactinomycin/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281012 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Filgrastim/Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281018 | mercaptopurine | Idarubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281119 | mercaptopurine | Asparaginase/Cytarabine/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281120 | mercaptopurine | Asparaginase/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281122 | mercaptopurine | Asparaginase/Dexamethasone/Doxorubicin/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281124 | mercaptopurine | Asparaginase/Dexamethasone/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281125 | mercaptopurine | Dexamethasone/Doxorubicin/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281126 | mercaptopurine | Dexamethasone/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281127 | mercaptopurine | Dexamethasone/Mercaptopurine/Methotrexate/Vincristine Combination | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281131 | mercaptopurine | Doxorubicin/Filgrastim/Mercaptopurine/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281212 | mercaptopurine | Asparaginase/Daunorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281213 | mercaptopurine | Cyclophosphamide/Cytarabine/Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281217 | mercaptopurine | Dexamethasone/Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281226 | mercaptopurine | Cytarabine/Etoposide/Ifosfamide/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281272 | mercaptopurine | Leucovorin Calcium/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281273 | mercaptopurine | Asparaginase/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281315 | mercaptopurine | Cytarabine/Mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281319 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Doxorubicin/Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281320 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281321 | mercaptopurine | Asparaginase/Daunorubicin/Dexamethasone/Ifosfamide/Mercaptopurine/Methotrexate/Vindesine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281363 | mercaptopurine | Asparaginase/Cytarabine/Dexamethasone/Doxorubicin/Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281364 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281365 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Dexamethasone/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281402 | mercaptopurine | Asparaginase/Cyclophosphamide/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0281403 | mercaptopurine | Cytarabine/Mercaptopurine/Methotrexate/Teniposide/Thioguanine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338125 | mercaptopurine | Interferon Alfa/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338168 | mercaptopurine | Interferon Alfa/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338220 | mercaptopurine | Cyclophosphamide/Cytarabine/Mercaptopurine/Pegaspargase/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338260 | mercaptopurine | Mercaptopurine/Methotrexate/Tretinoin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338264 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Etoposide/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338302 | mercaptopurine | Asparaginase/Dexrazoxane/Doxorubicin/Mercaptopurine/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338303 | mercaptopurine | Asparaginase/dexrazoxane/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338304 | mercaptopurine | Asparaginase/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338305 | mercaptopurine | Dexrazoxane/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338308 | mercaptopurine | Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338320 | mercaptopurine | Cyclophosphamide/Cytarabine/Etoposide/Mercaptopurine/Methotrexate/Prednisolone/Thioguanine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338331 | mercaptopurine | Mercaptopurine/Prednisolone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0338360 | mercaptopurine | Cyclophosphamide/Dexamethasone/Etoposide/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0678015 | mercaptopurine | Cyclophosphamide/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796447 | mercaptopurine | Asparaginase/Dexamethasone/Mercaptopurine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796449 | mercaptopurine | Dexamethasone/Leucovorin Calcium/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796450 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Dexamethasone/Mercaptopurine/Methotrexate/Thioguanine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796458 | mercaptopurine | Asparaginase/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796459 | mercaptopurine | Cytarabine/Mercaptopurine/Methotrexate/Prednisone | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796535 | mercaptopurine | Asparaginase/Cytarabine/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796536 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Mercaptopurine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796538 | mercaptopurine | Asparaginase/Leucovorin Calcium/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796540 | mercaptopurine | Asparaginase/Cytarabine/Dexamethasone/Leucovorin Calcium/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0796542 | mercaptopurine | Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Dexamethasone/Mercaptopurine/Methotrexate/Thioguanine/Vincristine/Vindesine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0879409 | mercaptopurine | Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate/Prednisone | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0879475 | mercaptopurine | Asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/thioguanine/vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0879561 | mercaptopurine | Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0935837 | mercaptopurine | Leucovorin Calcium/Mercaptopurine/Methotrexate/Prednisolone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0935841 | mercaptopurine | Leucovorin Calcium/Mercaptopurine/Methotrexate/Prednisolone | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0935846 | mercaptopurine | Mercaptopurine/Methotrexate/Nelarabine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0935859 | mercaptopurine | Cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisolone | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C0935860 | mercaptopurine | Cyclophosphamide/Cytarabine/Dexamethasone/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C1134461 | mercaptopurine | Cyclophosphamide/Dexamethasone/Etoposide/Imatinib Mesylate/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C1134462 | mercaptopurine | Dexamethasone/Imatinib Mesylate/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_gdc_value | C1254351 | mercaptopurine | Pharmacologic Substance | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve sy... |
C0000618 | chemotherapy_regimen_has_component | C1327949 | mercaptopurine | Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vinblastine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C1327984 | mercaptopurine | Cyclophosphamide/Cytarabine/Daunorubicin/Dexamethasone/Leucovorin Calcium/Mercaptopurine/Methotrexate/Pegaspargase/Thioguanine/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C1327985 | mercaptopurine | Leucovorin Calcium/Mercaptopurine/Methotrexate/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | is_physiologic_effect_of_chemical_or_drug | C1511701 | mercaptopurine | DNA Synthesis Inhibition | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | DNA Synthesis Inhibition involves interference with, or restraint of, the activities involved in the polymeric linkage of deoxyribose moieties (with adenine, guanine, cytosine, or thymine side chains) by phosphate groups attached to their 5-prime and 3-prime sugar hydroxyls. |
C0000618 | is_physiologic_effect_of_chemical_or_drug | C1514610 | mercaptopurine | Purine Synthesis Inhibition | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Purine Synthesis Inhibition involves interference with, or restraint of, the activities of biologic molecules or complexes involved in the enzymatic formation of purine nucleoside phosphates, monomeric building blocks from which DNA or RNA polymers are constructed. |
C0000618 | chemotherapy_regimen_has_component | C1521424 | mercaptopurine | 506U78/Mercaptopurine/Methotrexate | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | is_mechanism_of_action_of_chemical_or_drug | C1524081 | mercaptopurine | Enzyme Inhibition | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Enzyme Inhibition involves interference with, or restraint of, the function of a biological molecule that possesses catalytic activity. |
C0000618 | is_mechanism_of_action_of_chemical_or_drug | C1709285 | mercaptopurine | Nucleoside Analogue Incorporation | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Nucleoside Analogue Incorporation involves assimilation of nucleoside or nucleotide analogues into DNA or RNA. |
C0000618 | subset_includes_concept | C1880653 | mercaptopurine | FDA Established Names and Unique Ingredient Identifier Codes Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | The terminology that includes terms pertaining to FDA/USP Substance Registration System (SRS), which is to support health information technology initiatives by generating unique ingredient identifiers (UNIIs) for substances in drugs, biologics, foods, and devices. |
C0000618 | chemotherapy_regimen_has_component | C1881360 | mercaptopurine | Larson Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of five phases used for the treatment of adult lymphoblastic leukemia. The five phases include: induction, early intensification, central nervous system (CNS) prophylaxis and interim maintenance, late intensification and prolonged maintenance. |
C0000618 | chemotherapy_regimen_has_component | C1881944 | mercaptopurine | NHL-BFM-90 Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen used for the treatment of localized aggressive forms of childhood B-cell non-Hodgkin lymphoma, including lymphoblastic lymphoma. |
C0000618 | chemotherapy_regimen_has_component | C1881945 | mercaptopurine | NHL-BFM-95 Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A modified version of the NHL-BFM 90 regimen, employing a different methotrexate dosing schedule, used for the treatment of localized aggressive forms of childhood B-cell lymphoma, including lymphoblastic lymphoma. |
C0000618 | subset_includes_concept | C3899741 | mercaptopurine | CTRP Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Terminology that is used to support NCI's Clinical Trials Reporting Program (CTRP), a database that captures the required reporting data for all NCI-sponsored clinical trials. |
C0000618 | subset_includes_concept | C3899744 | mercaptopurine | CTRP Agent Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A subset of terminology about pharmacologic substances and formulations that are currently being used or tested in clinical trials for the treatment of cancer, cancer-related conditions and chemo/radiotherapy-related side effects. |
C0000618 | subset_includes_concept | C4288628 | mercaptopurine | NCIt Antineoplastic Agent Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A terminology subset in NCI Thesaurus (NCIt) containing any agent that has known or potential antineoplastic activity. The subset includes FDA approved antineoplastic agents, agents that either are or once were in clinical trial (CT) specifically for their antineoplastic activity as well as some additional investigatio... |
C0000618 | subset_includes_concept | C4763808 | mercaptopurine | GDC Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Terminology that supports the Genomic Data Commons (GDC). |
C0000618 | subset_includes_concept | C4763809 | mercaptopurine | GDC Therapeutic Agent Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C5202853 | mercaptopurine | DCCMP Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of daunorubicin, cyclocytidine, 6-mercaptopurine, and prednisone that may be used in the treatment of acute myeloid leukemia (AML). |
C0000618 | subset_includes_concept | C5447243 | mercaptopurine | NCI Drug Dictionary Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Terminology created to support the National Cancer Institute (NCI) Drug Dictionary. |
C0000618 | subset_includes_concept | C5447840 | mercaptopurine | GDC Value Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Terminology that supports the values for properties in the Genomic Data Commons (GDC) data model. |
C0000618 | chemotherapy_regimen_has_component | C5779653 | mercaptopurine | Mercaptopurine/Methotrexate/Prednisone/Vincristine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | chemotherapy_regimen_has_component | C5780861 | mercaptopurine | Cyclophosphamide/Cytarabine/Mercaptopurine/Pegaspargase/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cyclophosphamide, cytarabine, mercaptopurine, pegaspargase and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5781108 | mercaptopurine | Mercaptopurine/Methotrexate/Tretinoin Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of mercaptopurine, methotrexate and tretinoin that may be used for the treatment of acute promyelocytic leukemia (APL). |
C0000618 | chemotherapy_regimen_has_component | C5784970 | mercaptopurine | Cyclophosphamide/Cytarabine/Dexamethasone/Etoposide/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cyclophosphamide, cytarabine, dexamethasone, etoposide, mercaptopurine, methotrexate, pegaspargase and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5784972 | mercaptopurine | Mercaptopurine/Methotrexate/Pegaspargase/Prednisone/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of mercaptopurine, methotrexate, pegaspargase, prednisone and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5891071 | mercaptopurine | Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cyclophosphamide, cytarabine, mercaptopurine and methotrexate that can be used in the treatment of acute lymphoblastic leukemia (ALL). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.